Active, not recruitingPhase 2NCT05758922
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C Disease
Studying GM2 gangliosidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Azafaros A.G.
- Intervention
- AZ-3102 (Dose 1)(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2023 – 2024
Study locations (3)
- Hospital Pequeno Principe, Curitiba, Brazil
- Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Rio de Janeiro, Brazil
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05758922 on ClinicalTrials.govOther trials for GM2 gangliosidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07399704A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseAzafaros A.G.
- ACTIVE NOT RECRUITINGNCT06614569Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff DiseaseTerence Flotte
- RECRUITINGNCT05007990Caregiving Networks Across Disease Context and the Life CourseNational Human Genome Research Institute (NHGRI)